Latest Car T News

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit for FY25, marking the completion of its transformative Simply Stronger program that enhanced digital offerings and customer reach.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Webjet Group Limited reported steady FY25 EBITDA of $51.6 million, buoyed by rising international bookings despite domestic softness, and unveiled an ambitious FY30 strategy including the acquisition of Locomote to expand its business travel footprint.

Eagers Automotive has reported a robust first half of 2025, with revenue climbing nearly 19% and net profit rising 8.8%, while maintaining its interim dividend at 24 cents per share.

Smartgroup has delivered a robust half-year 2025 performance, marked by strong revenue growth, expanding customer base, and strategic advances in digital services and electric vehicle leasing.

Smartgroup Corporation has reported a robust first half of 2025, with a 12% rise in NPATA and nearly half of new car leases now electric vehicles. The company’s strategic digital initiatives and strong customer growth underpin its confident outlook.

Smartgroup Corporation Ltd reported a solid first half for 2025 with revenue up 7% and net profit rising 11%, powered by strong novated leasing growth amid shifting electric vehicle policies.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Alfabs Australia Limited reported a robust 76% rise in net profit for FY2025, driven by strong mining contract deliveries and engineering demand, while boosting dividends and expanding operational capacity.

Alfabs Australia Limited reported a robust 76% jump in net profit for FY2025, driven by mining equipment hire and new profit centres, while planning a significant $31 million capital expenditure for FY2026.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.